Moleculin Biotech Inc MBRX

NAS: MBRX | ISIN: US60855D1019   30/04/2025
1,060 USD (+3,92%)
(+3,92%)   30/04/2025

11 maart 2025 · Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference · Persbericht

10 maart 2025 · Moleculin to Present at the 37th Annual ROTH Conference · Persbericht

6 maart 2025 · Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity · Persbericht

3 maart 2025 · Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium · Persbericht

9 september 2024 · Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma · Persbericht

3 september 2024 · Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference · Persbericht

26 augustus 2024 · Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar · Persbericht

19 augustus 2024 · Moleculin Announces Closing of up to $16.5 Million Public Offering · Persbericht

16 augustus 2024 · Moleculin Announces Pricing of up to $16.5 Million Public Offering · Persbericht

14 augustus 2024 · Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

5 augustus 2024 · Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET · Persbericht

1 augustus 2024 · Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial · Persbericht

10 juli 2024 · Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML · Persbericht

14 juni 2024 · Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial · Persbericht

12 juni 2024 · Moleculin to Present at the Virtual Investor Pitch Conference · Persbericht

5 juni 2024 · Moleculin to Participate in the Virtual Investor Lunch Break Series · Persbericht

16 mei 2024 · Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress · Persbericht

15 mei 2024 · Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) · Persbericht

13 mei 2024 · Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

9 mei 2024 · Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin · Persbericht

Mijn selecties